In biotechnology circles, the idea that patents can be obtained on human genetic material is a given. It’s been a fact of life for nearly 30 years, since well before the word “biotechnology” came into wide use. Beyond the realms of biotech executives and patent lawyers, though, it’s a reality that many people find surprising–even shocking. Christopher Hansen is one of those people.
A senior staff attorney at the American Civil Liberties Union, Hansen first learned that human genes were subject to patents two years ago from ACLU science adviser Tania Simoncelli. He was so taken aback by the revelation, he recalls, that he told Simoncelli she was mistaken.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
